We aimed at comparing the impact of switching from efavirenz to rilpivirine in patients receiving efavirenz plus 2 nucleoside analogues versus continuing with the same therapy on hepatic steatosis as measured by controlled attenuation parameter (CAP) among HIV-infected patients with NAFLD. Efavirenz Rilpivirine Switching HIV NAFLD Fatty liver disease CAP
Conditions
Interventions
The group that switched from efavirenz to rilpivirine was changed to the following antiretroviral drugs
In the case of receiving 3 antiviral drugs and separate tablets for each type or two types of a
Active Comparator Drug,Active Comparator Drug
rilpivirine switching group,efavirenz continuous group
Sponsors
Thai AIDs Society
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. HIV-1 infected patient 2. Age >= 18-year-old 3. Efavirenz was given in combination with either Tenofovir or Abacavir, and either Emtricitabine or Lamivudine for more than 24 weeks. 4. HIV-viral load < 40 copies/mL for more than 24 weeks. 5. Hepatic steatosis when measured by Controlled attenuation parameter >= 248 dB / m. 6. History of drinking less than 30 grams of alcohol per day in men and less than 20 grams per day in women
Exclusion criteria
Exclusion criteria: 1. Pregnant patients 2. History of virologic failure or virologic resistance 3. History of opportunistic infections in the past 24 weeks 4. Patients with contraindications to rilpivirine, for example receiving all proton pump inhibitors. 5. Infected with hepatitis B virus or hepatitis C virus 6. BMI more than 30 Kg/m2 7. Patients using drugs corticosteroid, methotrexate, amiodarone, valproate 8. Patients diagnosed with autoimmune hepatitis, hemochromatosis, Wilson's disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change of controlled attention parameter 24 weeks after randomization fibroscan | — |
Secondary
| Measure | Time frame |
|---|---|
| change of hepatic fibrosis 24 weeks after randomization fibroscan,Effect on metabolic conditions 24 week after randomization body weight, body mass index, waist circumference, Fasting blood sugar and lipid profile | — |
Countries
Thailand
Contacts
Public ContactLaddarat Srikham
Infectious division, internal medicine department. King Chulalongkorn Memorial Hospital
Outcome results
None listed